Contributors: Reni, M.; Giommoni, E.; Bergamo, F.; Milella, M.; Cavanna, L.; Di Marco, M. C.; Spada, M.; Cordio, S.; Aprile, G.; Cardellino, G. G.; Maiello, E.; Bernardini, I.; Ghidini, M.; Bozzarelli, S.; Macchini, M.; Orsi, G.; De Simone, I.; Rulli, E.; Porcu, L.; Torri, V.; Pinto, C.; Peretti, U.; Valente, M.; Antonuzzo, L.; Di Costanzo, F.; Zagonel, V.; Lonardi, S.; Buggin, F.; Palmerio, S.; Di Nunzio, C.; Grassi, E.; Messina, M.; Avola, F.; Pagano, S.; Simionato, F.; Majer, F.; Latiano, T. P.; Chiarazzo, C.; Artioli, F.; Razzini, G.; Pasqualini, A.; Binda, E.; Lazzarelli, S.; Sala, S.; Luppi, G.; Pettorelli, E.; Spallanzani, A.; Vicario, G.; Salmaso, F.; Basso, M.; Silvestris, N.; Del Curatolo, S.; Zustovich, F.; Bongiovanni, F.; Longobardi, C.; Sandi, I.; Fontanella, C.; Montelatici, S.; Giordano, M.; Luchena, G.; Gilardoni, M.; Tamburini, E.; Rudnas, B.; Venturini, B.; Merelli, B.; Negrini, G.; Vici, E. M.; Marabese, A.; Garetto, C.; Curcio, P.; Cinieri, S.; Cinefra, M.; Ferrara, P.; Cantore, M.; Morselli, P.; Fumi, G.; Isidori, A.; Ciccarese, G.; Paolo Frassineti, G. L.; Pagan, F.; Vaccaro, V.; Spoto, C.; Ferrara, M.; Garufi, C.; Caporale, M.; Vasile, E.; Salani, F.; Barone, E.; Berardi, R.
نبذة مختصرة : Background: Information about the adherence to scientific societies guidelines in the ‘real-world’ therapeutic management of oncological patients are lacking. This multicenter, prospective survey was aimed to improve the knowledge relative to 2017-2018 recommendations of the Italian Association of Medical Oncology (AIOM). Patients and methods: Treatment-naive adult patients with pancreatic adenocarcinoma were enrolled. Group A received adjuvant therapy, group B received primary chemotherapy, and group C had metastatic disease. The results on patients accrued until 31 October 2019 with a mature follow-up were presented. Results: Since July 2017, 833 eligible patients of 923 (90%) were enrolled in 44 Italian centers. The median age was 69 years (range 36-89 years; 24% >75 years); 48% were female; 93% had Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; group A: 16%, group B: 30%; group C: 54%; 72% Nord, 13% Center, 15% South. In group A, guidelines adherence was 68% [95% confidence interval (CI) 59% to 76%]; 53% of patients received gemcitabine and 15% gemcitabine + capecitabine; median CA19.9 was 29 (range 0-7300; not reported 15%); median survival was 36.4 months (95% CI 27.5-47.3 months). In group B, guidelines adherence was 96% (95% CI 92% to 98%); 55% of patients received nab-paclitaxel + gemcitabine, 27% FOLFIRINOX, 12% gemcitabine, and 3% clinical trial; median CA19.9 was 337 (range 0-20220; not reported 9%); median survival was 18.1 months (95% CI 15.6-19.9 months). In group C, guidelines adherence was 96% (95% CI 94% to 98%); 71% of patients received nab-paclitaxel + gemcitabine, 16% gemcitabine, 8% FOLFIRINOX, and 4% clinical trial; liver and lung metastases were reported in 76% and 23% of patients, respectively; median CA19.9 value was 760 (range 0-1374500; not reported 9%); median survival was 10.0 months (95% CI 9.1-11.1 months). Conclusions: The GARIBALDI survey shows a very high rate of adherence to guidelines and survival outcome in line with the literature. ...
Processing Request
No Comments.